Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma, Version 2.2024

Shaji K. Kumar, Natalie S. Callander, Kehinde, Md, Msci Adekola, Larry D. Anderson, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Christopher D'Angelo, Benjamin Derman, Srinivas Devarakonda, Noura Elsedawy, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin HultcrantzYubin Kang, Sarah Larson, Hans Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy Robinson, Aaron Rosenberg, Douglas Sborov, Mark A. Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Nina Varshavsky-Yanovsky, Jenna Snedeker, Rashmi Kumar

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.

Original languageEnglish
Article numbere240001
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume22
Issue number1
DOIs
StatePublished - Jan 2024

Fingerprint

Dive into the research topics of 'Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma, Version 2.2024'. Together they form a unique fingerprint.

Cite this